Company Overview
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment protection and packaging for firearms, unmanned aerial vehicles/drones, weapon systems, electronic devices communications equipment, and tools and repair kits; cushion and protective packaging; acoustic and thermal insulation components for automotive, aerospace, consumer, and industrial; filtration for small engines, air conditioners, humidifiers, refrigerators, electronic air cleaners, forced air appliances and industrial compressors; fluid management; and seals and gaskets for automotive manufacturing chemical processing, building and construction applications. In addition, the company provides uniform and tactical gear, such as backpack straps and padding, uniform knee and elbow pads, duty belts, holsters, and helmet padding and others; sports and leisure including custom helmet linings, athletic braces, and shoe insoles; and trim and structural components, consist of load floors, sunshades, package trays, back panel, and seat backs. The company serves the medical, aerospace and defence, automotive, consumer, electronics, and industrial markets. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Why Investors Should Care
Generates a return on equity of 17.2%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 15.9%.
Net profit has compounded at 16.5% per year over the last five years.
Revenue has grown at a 11.9% CAGR over the past five years.
Operating margin of 15.1% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.36.
Recent Developments
- Dec 2025 Revenue of $602.80M (+19.5% YoY); net profit $68.31M.
- Trailing 12 Months Year-on-year growth — revenue +4.1%, earnings +1.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.9%, profit CAGR 16.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.94% |
| 1 Year: | 4.10% |
Compounded Profit Growth
| 5 Years: | 16.50% |
| 1 Year: | 1.40% |
Stock Price Performance
| 1 Year: | +0.13% |
| 6 Months: | -5.01% |
| 3 Months: | +25.46% |
| 1 Month: | +4.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.63 · Neutral
P/E of 27.98 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.9% over 5 years.
- Profit CAGR of 16.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UFPT UFP Technologies, Inc. R2K | 245.93 | 27.98 | $1.90B | 0.00% | 15.91% | 17.17% | 11.94% | 16.50% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.75M | 100.04M | 100.78M | 101.50M | 105.01M | 110.18M | 145.16M | 144.07M | 148.15M | 151.18M | 154.56M | 148.91M | 154.20M |
| Gross Profit | 10.29M | 8.45M | 8.18M | 9.52M | 9.94M | 8.19M | 7.84M | 10.19M | 12.99M | 12.43M | 12.71M | 12.50M | 14.37M | 13.32M | 13.77M | 12.82M | 9.95M | 10.53M | 11.38M | 12.61M | 13.41M | 12.02M | 13.07M | 17.13M | 24.32M | 25.52M | 23.28M | 28.70M | 29.64M | 27.75M | 26.13M | 30.08M | 33.03M | 41.52M | 42.06M | 42.15M | 43.54M | 42.75M | 41.97M | 44.36M |
| Operating Income | 4.19M | 4.08M | - | 3.21M | 3.93M | 2.50M | - | 2.56M | 5.67M | 5.88M | - | 5.25M | 6.57M | 6.14M | - | 5.08M | 2.99M | 3.73M | - | 5.30M | 6.21M | 5.08M | - | 6.36M | 12.20M | 25.96M | - | 12.84M | 17.04M | 15.04M | - | 15.92M | 17.95M | 24.76M | - | 23.13M | 24.33M | 23.38M | - | 23.37M |
| Net Income | 2.73M | 2.67M | - | 2.17M | 2.63M | 1.70M | - | 1.78M | 3.99M | 4.13M | - | 3.73M | 4.60M | 5.64M | - | 3.89M | 2.32M | 2.99M | - | 4.16M | 4.71M | 3.79M | - | 4.86M | 8.93M | 19.54M | - | 9.74M | 11.88M | 11.69M | 11.61M | 12.69M | 13.55M | 16.36M | 16.38M | 17.18M | 17.18M | 16.38M | 17.57M | 17.50M |
| Diluted EPS | 0.38 | 0.37 | 0.20 | 0.30 | 0.36 | 0.23 | 0.37 | 0.24 | 0.54 | 0.56 | 0.59 | 0.00 | 0.62 | 0.75 | 0.77 | 0.52 | 0.31 | 0.40 | 0.55 | 0.55 | 0.62 | 0.50 | 0.42 | 0.64 | 1.17 | 2.56 | 1.10 | 1.27 | 1.55 | 1.52 | 1.51 | 1.64 | 1.75 | 2.11 | 2.10 | 2.21 | 2.21 | 2.11 | 2.25 | 2.24 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 99.23M | 120.77M | 127.24M | 130.96M | 139.22M | 139.31M | 138.85M | 146.13M | 147.84M | 190.46M | 198.38M | 179.37M | 206.32M | 353.79M | 400.07M | 504.42M | 602.80M |
| Gross Profit | 26.72M | 34.62M | 36.24M | 38.32M | 41.01M | 36.88M | 37.45M | 34.65M | 35.49M | 48.31M | 53.96M | 44.68M | 51.11M | 90.26M | 112.22M | 146.69M | 170.41M |
| Operating Income | 8.19M | 14.39M | 15.72M | 16.67M | 17.40M | 11.56M | 11.71M | 12.24M | 11.69M | 19.61M | 24.71M | 16.73M | 21.22M | 55.40M | 57.66M | 80.90M | 92.34M |
| Net Income | 5.93M | 9.25M | 10.35M | 10.89M | 11.28M | 7.56M | 7.59M | 7.97M | 9.21M | 14.31M | 19.75M | 13.37M | 15.89M | 41.79M | 44.92M | 58.98M | 68.31M |
| Diluted EPS | 0.94 | 1.37 | 1.48 | 1.55 | 1.59 | 1.05 | 1.05 | 1.10 | 1.26 | 1.93 | 2.63 | 1.77 | 2.09 | 5.45 | 5.83 | 7.58 | 8.75 |
| R&D Expense | - | 900.00K | 1.20M | 1.30M | 1.20M | 1.40M | 1.30M | 1.30M | 5.00M | 10.50M | 8.80M | 8.20M | 8.50M | 9.30M | 7.20M | 10.40M | 8.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 69.48M | 79.72M | 98.62M | 104.91M | 112.55M | 119.64M | 127.93M | 138.21M | 189.60M | 188.76M | 203.20M | 334.13M | 378.19M | 404.14M | 629.00M | 655.08M |
| Total Equity | 31.89M | 39.01M | 49.70M | 61.31M | 73.26M | 85.59M | 94.99M | 103.57M | 113.05M | 123.71M | 140.46M | 161.99M | 176.89M | 194.45M | 237.54M | 286.09M | 342.76M | 423.88M |
| Cash & Equivalents | 5.14M | 13.40M | 22.10M | 29.85M | 33.48M | 37.30M | 34.05M | 29.80M | 31.36M | 37.98M | 3.24M | 3.74M | 24.23M | 11.12M | 4.45M | 5.26M | 13.45M | 20.30M |
| Long Term Debt | - | - | 6.85M | 5.64M | 8.31M | 2.87M | 1.87M | 859.00K | 856.00K | - | 22.29M | - | 0 | 71.00M | 51.00M | 28.00M | 176.88M | 122.95M |
| Total Liabilities | - | - | 19.25M | 17.74M | 25.36M | 19.32M | 17.56M | 16.06M | 14.88M | 14.49M | 49.14M | 26.77M | 26.31M | 139.69M | 140.65M | 118.05M | 286.24M | 231.20M |
| Current Liabilities | - | - | 10.17M | 9.47M | 13.23M | 12.32M | 11.61M | 10.67M | 9.56M | 9.94M | 20.66M | 16.78M | 15.14M | 38.78M | 55.96M | 58.21M | 76.30M | 74.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | 12.52M | 9.31M | 17.47M | 21.32M | 31.23M | 25.04M | 14.29M | 17.74M | 41.33M | 66.59M | 91.91M |
| Investing Cash Flow | - | - | - | - | - | - | -15.69M | -7.19M | -10.38M | -82.33M | -5.77M | -4.26M | -101.46M | 1.29M | -10.49M | -210.16M | -27.60M |
| Financing Cash Flow | - | - | - | - | - | - | -1.08M | -559.00K | -475.00K | 26.27M | -24.95M | -285.00K | 74.05M | -25.89M | -30.02M | 152.39M | -58.16M |
| Capital Expenditure | -1.86M | -3.29M | -3.74M | -11.99M | -5.83M | -13.44M | -15.74M | -7.21M | -10.38M | -5.43M | -5.78M | -4.37M | -5.39M | -13.78M | -10.49M | -9.66M | - |
| Free Cash Flow | - | - | - | - | - | - | -3.22M | 2.10M | 7.09M | 15.89M | 25.45M | 20.67M | 8.90M | 3.96M | 30.84M | 56.94M | - |
| Share Buybacks | - | - | - | - | - | - | 587.00K | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 26.9% | 28.7% | 28.5% | 29.3% | 29.5% | 26.5% | 27.0% | 23.7% | 24.0% | 25.4% | 27.2% | 24.9% | 24.8% | 25.5% | 28.1% | 29.1% | 28.3% |
| Operating Margin % | 8.3% | 11.9% | 12.4% | 12.7% | 12.5% | 8.3% | 8.4% | 8.4% | 7.9% | 10.3% | 12.5% | 9.3% | 10.3% | 15.7% | 14.4% | 16.0% | 15.3% |
| Net Margin % | 6.0% | 7.7% | 8.1% | 8.3% | 8.1% | 5.4% | 5.5% | 5.5% | 6.2% | 7.5% | 10.0% | 7.5% | 7.7% | 11.8% | 11.2% | 11.7% | 11.3% |
| ROE % | 15.2% | 18.6% | 16.9% | 14.9% | 13.2% | 8.0% | 7.3% | 7.0% | 7.4% | 10.2% | 12.2% | 7.6% | 8.2% | 17.6% | 15.7% | 17.2% | 16.1% |
| ROCE % | - | 24.3% | 22.4% | 19.5% | 18.8% | 11.5% | 10.8% | 10.3% | 9.1% | 11.6% | 14.4% | 8.9% | 7.2% | 17.2% | 16.7% | 14.6% | 15.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.18% | 1.10M | $266.24M |
| 2 | Congress Asset Management Co | 8.89% | 687.44K | $166.81M |
| 3 | Wasatch Advisors LP | 8.83% | 683.26K | $165.80M |
| 4 | Vanguard Capital Management LLC | 4.22% | 326.73K | $79.28M |
| 5 | Boston Trust Walden Corporation | 4.10% | 317.07K | $76.94M |
| 6 | State Street Corporation | 3.92% | 303.31K | $73.60M |
| 7 | Neuberger Berman Group, LLC | 3.89% | 300.59K | $72.94M |
| 8 | Price (T.Rowe) Associates Inc | 3.19% | 246.50K | $59.82M |
| 9 | Thrivent Financial For Lutherans | 3.07% | 237.28K | $57.58M |
| 10 | Massachusetts Financial Services Co. | 2.94% | 227.30K | $55.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UFPT
Diversify Wealth Management LLC Has $1.70 Million Stake in UFP Technologies, Inc. $UFPT - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQQ2VZeWFEM2VMNWlYdWJ6QU92cWFVWnVGdWZuMkNwYTc5SkVDdWlrQjVZekhwRnJRT0duU2dhSW81a0lCU3NrQUYzSFdCQXZ6VUxqY3BTcGJPZ1hleEFySGpOcmE0U25ZUkVmUm9pb0ZvOVVuLWd5bFEzMjNjcjZiRGtMVk45YV8xeERUMT…
Price to book forward of UFP Technologies, Inc. – NASDAQ:UFPT - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQb3FHMTJSZ0wwWkZJQjVyS0VIN3BjcFZBWmxDOGR5dkZEbS1HaW1WNm5INlgxYjM3R2NWNXhFMmUwMXhZcVlmVEFYQVo4S3BPOERDQWdxcTQwT3d1WFdsekVqbUZPWXEtYWRUQnU0OFVPYmQwNUpTRjhaNm1Dd2tHQVR1TWhRTFNSYkc4X1…
UFP Technologies sends CEO, CFO to CJS investor conference July 9 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQTjRidWVjWWNna2NzUFV3MVQ5TEFFQkE2b0duOHVINXctQWdsQ2xQSGFQb2FOV0ZhWS1kMzF2RHFQNzAteG8yMk13Ul9iSnVXdDhuU3Npem5BRm5uZzZ3TUZGZVJpZUExZWNidmc0RGhhOGpYSkIwUVpyNEZIUHhLNkdRREhfdkcxUVhCTU…
Behavioral Patterns of UFPT and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNM3U5SXIzV0ZNeGsxa20yb3AtYmNFRTVxV2dWLVVidUJOeTBzQndDWHFHME9UanJPTGlDUmRjVlI0b3JIZUxaZkhjMURJcU43OGtRZVdEUm1zWVEwT2JQdlJzQnV3WGxiUnVSX1VqT3V3TGw2OWNjWE9CNEhMeGNOWnpzS04zLUMyOFFQTW…
UFP Technologies (UFPT) Tops Q1 Earnings Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNUy0wNFR3SG02OEpOQjZvMFFRSEFxYVk4dDVUNnNpQVNMMkdiNUtaR1VwREVsRHluNElYQ0NwQUpEWllVaUZXR3U4cGhuX1hRTy1sWk43SEVPei02TGY3YjU2T1NkckxFbS1xSE9kNE9MelY4SnlqU1dMdlNJWGFoZzlRMlBwSE5BSFB2M2…
UFP Technologies Inc (UFPT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi_wJBVV95cUxNVkFwMWFac0lxVDlvcGM0Ti1yMXdENHJ5SnF2Z2pxTklMMmxlTG5vNkcwelU5N3podmJndFBrT0hyWXNzSkh3Rk1KREpzak1fVWF4R3RjM0IzdDlPMENhMFlOTXNyRDRMQUxGMkgtV3FsM29rVXhzb19mYllDYXN4NVRwVmFJZTBkc1RKaU…
UFPT — Frequently Asked Questions
What is the current share price of UFP Technologies, Inc. (UFPT)?
As of 2026-07-15 16:51 PDT, UFP Technologies, Inc. (UFPT) trades at $245.93 on NasdaqCM. Its 52-week range is $185.28 to $272.36.
What is the market capitalisation of UFPT?
UFP Technologies, Inc. (UFPT) has a market capitalisation of $1.90B on NasdaqCM.
What is the P/E ratio of UFPT?
UFPT trades at a trailing price-to-earnings (P/E) ratio of 27.98. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 4.28.
What is the return on equity (ROE) of UFPT?
UFPT has a return on equity (ROE) of 17.17%. Its return on capital employed (ROCE) is 15.91%.
Is UFPT a good stock to buy?
This page provides a data-driven analysis of UFP Technologies, Inc. (UFPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.